Active Ingredient(s): Cemiplimab-rwlc
FDA Approved: * September 28, 2018
Category: Cancer

* This drug may consist of multiple approval dates, manufacturers, or distributors. If applicable, they would be listed below under "NDC Database Records".

Libtayo Overview

Cemiplimab (REGN-2810) is a monoclonal antibody under development as a drug for the treatment of squamous cell skin cancer,[1] myeloma,[2] and lung cancer.[3] In Sept 2018 it was approved by the US FDA for treating "patients with metastatic cutaneous squamous cell carcinoma (CSCC) or locally advanced CSCC who are not candidates for curative surgery or curative radiation". [4] cemiplimab-rwlc will be marketed as Libtayo.[4...

Read more Libtayo Details
Details May Include Instructions, Side Effects, Interactions, Etc. Drug monograph is from Wikipedia. All text is available under the terms of the GFDL (GNU Free Documentation License). Source:

Recent Libtayo Forums:

Be the first to start a discussion about this drug.

Possible Dosages for this and Related Drugs:

  • Injection: 350mg
Note: Above list includes dosages for all drugs with the same combination of active ingredients.

NDC Database Records for Libtayo: (1 result)

Sorted by National Drug Code
  • 61755-008 Libtayo 50 mg/ml Intravenous Injection by Regeneron Pharmaceuticals, Inc.

Other drugs which contain Cemiplimab-rwlc or a similar ingredient: (1 result)

Note: All times displayed are GMT - 7.

This information has been independently compiled and is for informational purposes only. It is not intended to be a substitute for medical advice from a qualified healthcare professional; nor is it intended to diagnose, treat, cure or prevent any disease. For more details please see the Medical Disclaimer. This page was last updated on 21 May 2019.

We are committed to your privacy.

Copyright © 2005-2019 All Rights Reserved. MedsChat® is a registered trademark of Limelight Innovations L.L.C. 9888 W Belleview Ave #5000, Denver, CO, 80123, USA